Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Adicet Bio: A Cheap Gamma Delta T-Cell Play
14.08.2026 13:18
Adicet Bio trades below cash ahead of a pivotal 3Q 2026 lupus nephritis CAR-T readout. Click here to read more about the ACET stock.
Bristol Myers Squibb to build $2.3 billion Houston campus
10.08.2026 17:37
The roughly 600,000-square-foot facility at Generation Park will create nearly 500 permanent jobs and about 2,000 construction positions
Major pharmaceutical company plans $2.3B Houston manufacturing campus, 500 jobs
10.08.2026 16:27
A major pharmaceutical company plans to invest approximately $2.3 billion in a new manufacturing campus in Houston, a project expected to create nearly 500 jobs. Gov. Greg Abbott announced Monday that Bristol Myers Squibb will establish the new pharmaceutical manufacturing campus at Generation Park in Harris County. The New Jersey-based global biopharmaceutical company focuses on discovering, developing and delivering medicines for serious diseases.
Bristol Myers Squibb plans $2.3 billion Houston manufacturing campus
10.08.2026 14:27
Bristol Myers Squibb (NYSE:BMY) has unveiled plans to invest approximately $2. 3 billion in a new manufacturing campus at Generation Park in Houston, Texas, as the pharmaceutical group expands its production capabilities in the United States.
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
10.08.2026 14:17
REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
10.08.2026 13:01
PRINCETON, N.J., August 10, 2026--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Interest Rates Could Still Rise in September: 5 High-Yield Passive Income Stocks Will Benefit
10.08.2026 12:15
Surging oil prices, a CPI spike not seen in three years, and Treasury yields at levels last touched in 2007 are forcing a September rate decision that could reshape which stocks lead the market through the rest of 2026.
Bristol Myers Squibb To Invest $2.3B In Houston Manufacturing Campus, Creating Nearly 500 Jobs
10.08.2026 09:04
New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation MedicinesInvestment Furthers BMS’ $40 Billion Commitment to American Innovation, Manufacturing and
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
07.08.2026 16:36
Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.
AstraZeneca (LSE:AZN) Merger Talk Fades, Is The Stock Undervalued?
07.08.2026 15:16
AstraZeneca (LSE:AZN) is back in focus after a senior source told Reuters that there are no ongoing merger discussions with Bristol Myers Squibb, reversing earlier headlines around a potential $400b pharmaceutical tie up. See our latest analysis for AstraZeneca. The clarification on merger talks comes after a sharp swing in AstraZeneca’s share price, which fell over recent weeks with a 30 day share price return of 17.5% decline and a year to date share price return of 12.8% decline. In...
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
07.08.2026 07:49
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanced cutaneous melanoma.
How the FTSE became a ‘departure lounge’ for British companies
07.08.2026 05:00
On holiday in Devon this summer, Charles Hall felt a familiar sinking feeling.
Schrödinger and BMS expand partnership to deploy AI for drug discovery
06.08.2026 10:01
The new arrangement will extend the use of Schrödinger’s technologies, including Bunsen and RetroSynth, throughout BMS’s teams.
Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?
06.08.2026 06:09
In the past few days, Schrödinger, Inc. reported second-quarter 2026 results showing revenue of US$58.89 million and a shift to a US$5.98 million net profit, while also expanding its long-running collaboration with Bristol Myers Squibb to deploy its new agentic AI co-scientist, Bunsen, across that partner’s research organization. Alongside this earnings turnaround, Schrödinger’s AI agreement with Bristol Myers Squibb and the related ESOP shelf registration highlight both growing adoption of...
Schrodinger Q2 Earnings Call Highlights
06.08.2026 05:03
Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter
Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says
04.08.2026 15:18
Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result
Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats
04.08.2026 14:56
Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph
Brokers split on AstraZeneca merger talk as shares recover some ground
04.08.2026 14:32
Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a...
BioNTech Q2 Earnings Call Highlights
04.08.2026 14:04
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
04.08.2026 13:40
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.